RxDoctor Payments Data

Rodrigo Crespo

Internal Medicine · Castroville, TXNPI 1609854090

Payments from drug & device makers

$14,174in general payments, 2019–2025

Across 590 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$983
  • Lilly USA, LLC$972
  • Johnson & Johnson$838
  • Boehringer Ingelheim$811
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,166100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)105$1,427
AstraZeneca(2 entities)36$1,201
Novo Nordisk59$983
Lilly USA, LLC64$972
Johnson & Johnson19$838
Boehringer Ingelheim34$811
Amarin Pharma, Inc.36$668
Merck30$555
Amgen(2 entities)12$494
GSK11$494
Nevro Corp.8$446
Axsome Therapeutics, Inc.12$416
Bayer10$292
Sunovion Pharmaceuticals Inc.15$261
Sanofi-aventis U.S. LLC14$252
Phathom Pharmaceuticals, Inc.2$250
E.r. Squibb & Sons, L.L.C.2$236
Corcept Therapeutics7$235
Radius Health, Inc.5$211
Inspire Medical Systems, Inc.4$207
Globus Medical3$179
Althera Pharmaceuticals LLC5$174
Astellas Pharma US Inc4$168
Si-bone, Inc.3$164
Dexcom, Inc.3$158
Edwards Lifesciences2$155
Novartis8$148
Stryker2$146
Pfizer10$143
Actelion Pharmaceuticals US, Inc.1$125
Esperion Therapeutics, Inc.7$117
Intuity Medical Inc1$116
Ultragenyx Pharmaceutical Inc.5$104
Abbott4$82
Biogen4$80
Corium, LLC3$78
Intuitive Surgical2$73
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$63
Takeda Pharmaceuticals U.S.A., Inc.3$60
Biohaven Pharmaceutical Holding Company Ltd.3$55
Teva Pharmaceuticals USA, Inc.3$41
Azurity Pharmaceuticals, Inc.2$37
Hologic Sales And Service, LLC1$35
Tolmar, Inc.2$34
Shield Therapeutics Inc2$34
Genentech USA, Inc.2$34
Vertex1$33
Seqirus USA Inc2$31
Biohaven Pharmaceuticals, Inc.1$25
GE HealthCare1$24
Impel Pharmaceuticals Inc.1$22
Helsinn Therapeutics (U.S.), Inc.1$22
Sumitomo Pharma America, Inc.1$22
Regeneron Healthcare Solutions, Inc.1$21
Bristol Myers Squibb1$21
Viatris Specialty LLC1$21
ANI Pharmaceuticals, Inc.1$20
Bausch Health US, LLC1$17
Circassia Inc.1$16
Assertio Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,174 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$135,786
Medicare patients
487
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide170$207,856
TrulicityDulaglutide94$122,356
JardianceEmpagliflozin105$117,205
EliquisApixaban91$90,056
MounjaroTirzepatide63$76,841
FarxigaDapagliflozin Propanediol70$64,105
LinzessLinaclotide72$47,724
JanuviaSitagliptin Phosphate42$46,706
XareltoRivaroxaban41$43,873
MyrbetriqMirabegron55$42,743
XifaxanRifaximin11$36,204
TrintellixVortioxetine Hydrobromide25$28,611
VascepaIcosapent Ethyl47$25,740
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$25,389
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$983$207,856170 claims
Lilly USA, LLCTrulicity, Mounjaro$972$199,197157 claims
Boehringer IngelheimJardiance, Tradjenta$811$134,515117 claims
PfizerEliquis$143$90,05691 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$1,201$84,558115 claims
MerckJanuvia, Janumet$555$68,59864 claims
AbbVieLinzess, Synthroid$1,427$52,496146 claims
Johnson & JohnsonXarelto$838$43,87341 claims
Astellas Pharma US IncMyrbetriq$168$42,74355 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$63$36,20411 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$60$28,61125 claims
GSKTrelegy Ellipta$494$23,14829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Castroville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →